Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AMRNNASDAQ:IMGONASDAQ:KNTENYSE:NUVB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$0.88$0.99$0.65▼$1.49$360.82M1.981.99 million shs657,243 shsIMGOImago BioSciences$36.01$35.96$11.56▼$36.09$1.22B2.82171,367 shsN/AKNTEKinnate Biopharma$2.65-0.4%$2.59$1.04▼$7.18$125.13M1.38418,678 shs2.81 million shsNUVBNuvation Bio$2.65-1.1%$2.55$0.95▼$4.16$584.36M1.371.99 million shs1.27 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-0.53%-4.20%+4.11%-30.27%-31.36%IMGOImago BioSciences0.00%0.00%0.00%0.00%0.00%KNTEKinnate Biopharma0.00%0.00%0.00%+10.42%+1.34%NUVBNuvation Bio-0.75%-1.12%+17.52%+54.97%+60.61%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.2035 of 5 stars1.93.00.00.00.00.00.6IMGOImago BioSciencesN/AN/AN/AN/AN/AN/AN/AN/AKNTEKinnate Biopharma4.3243 of 5 stars3.05.00.04.70.03.31.3NUVBNuvation Bio3.7881 of 5 stars4.53.00.00.03.13.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin1.75Reduce$1.0823.30% UpsideIMGOImago BioSciencesN/AN/AN/AN/AKNTEKinnate Biopharma2.00Hold$8.15207.45% UpsideNUVBNuvation Bio3.00Buy$6.60149.06% UpsideCurrent Analyst RatingsLatest AMRN, IMGO, KNTE, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2024NUVBNuvation BioRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$4.00 ➝ $5.003/28/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/27/2024NUVBNuvation BioJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$1.40 ➝ $10.003/26/2024NUVBNuvation BioBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.003/7/2024NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.50 ➝ $5.003/1/2024NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.002/26/2024KNTEKinnate BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$2.592/16/2024KNTEKinnate BiopharmaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$306.91M1.18N/AN/A$1.35 per share0.65IMGOImago BioSciencesN/AN/AN/AN/A$6.40 per shareN/AKNTEKinnate BiopharmaN/AN/AN/AN/A$5.06 per shareN/ANUVBNuvation BioN/AN/AN/AN/A$2.76 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$0.14N/AN/AN/A-19.26%-10.47%-6.97%5/1/2024 (Confirmed)IMGOImago BioSciences-$42.31M-$1.84N/AN/AN/AN/A-31.85%-30.07%N/AKNTEKinnate Biopharma-$116.27M-$2.78N/AN/AN/AN/A-62.31%-54.72%5/9/2024 (Estimated)NUVBNuvation Bio-$75.80M-$0.34N/AN/AN/AN/A-12.21%-11.89%5/2/2024 (Estimated)Latest AMRN, IMGO, KNTE, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AAMRNAmarin-$0.0350N/A+$0.0350N/AN/AN/A 2/29/2024Q4 2023AMRNAmarin-$0.05-$0.01+$0.04-$0.01$72.46 million$74.71 million2/29/2024Q4 2023NUVBNuvation Bio-$0.10-$0.06+$0.04-$0.06N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/AIMGOImago BioSciencesN/AN/AN/AN/AN/AKNTEKinnate BiopharmaN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A2.801.80IMGOImago BioSciencesN/A13.1513.16KNTEKinnate BiopharmaN/A10.8010.80NUVBNuvation BioN/A44.1144.11OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%IMGOImago BioSciences91.53%KNTEKinnate Biopharma80.89%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%IMGOImago BioSciences14.90%KNTEKinnate Biopharma41.70%NUVBNuvation Bio36.09%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin275410.67 million402.62 millionOptionableIMGOImago BioSciences2733.82 million28.78 millionNot OptionableKNTEKinnate Biopharma8447.22 million27.53 millionOptionableNUVBNuvation Bio51218.05 million139.35 millionOptionableAMRN, IMGO, KNTE, and NUVB HeadlinesSourceHeadlineNuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingbusinesswire.com - April 24 at 10:01 AMNuvation Bio (NYSE:NUVB) Trading Up 5%americanbankingnews.com - April 21 at 2:32 AMNuvation Bio (NYSE:NUVB) Stock Price Up 5%marketbeat.com - April 19 at 11:58 AMRoyal Bank of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $5.00americanbankingnews.com - April 19 at 5:00 AMNuvation Bio (NYSE:NUVB) Shares Gap Up Following Analyst Upgradeamericanbankingnews.com - April 18 at 1:12 AMNuvation Bio Stock (NYSE:NUVB), Analyst Ratings, Price Targets, Predictionsbenzinga.com - April 17 at 8:28 PMNuvation Bio (NYSE:NUVB) Price Target Raised to $5.00 at Royal Bank of Canadamarketbeat.com - April 17 at 3:56 PMNuvation Bio (NYSE:NUVB) Shares Gap Up After Analyst Upgrademarketbeat.com - April 17 at 3:50 PMStrategic Acquisition Bolsters Nuvation Bio’s Growth Potential and Pipeline Prospectsmarkets.businessinsider.com - April 13 at 8:49 AMNuvation Bio (NYSE:NUVB) Trading 3.9% Higher marketbeat.com - April 11 at 1:48 PMNuvation Bio (NYSE:NUVB) Trading Down 8.4%marketbeat.com - April 10 at 4:23 PMNuvation Bio Completes Acquisition of AnHeart Therapeuticsbusinesswire.com - April 10 at 4:01 PMAssenagon Asset Management S.A. Has $1.12 Million Position in Nuvation Bio Inc. (NYSE:NUVB)marketbeat.com - April 6 at 4:40 AMNuvation Bio (NYSE:NUVB) Shares Down 6.5% marketbeat.com - April 2 at 3:17 PMWeek In Review: AriBio Sells China Rights To Alzheimer's Candidate In $770M Dealseekingalpha.com - March 31 at 7:56 AMNuvation Bio (NYSE:NUVB) Sees Unusually-High Trading Volume Following Analyst Upgrademarketbeat.com - March 28 at 10:31 AMNuvation Bio (NYSE:NUVB) PT Raised to $8.00 at HC Wainwrightmarketbeat.com - March 28 at 8:45 AMQ2 2024 EPS Estimates for Nuvation Bio Inc. Increased by Wedbush (NYSE:NUVB)marketbeat.com - March 28 at 8:43 AMNuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officerbusinesswire.com - March 28 at 8:00 AMNuvation Bio (NYSE:NUVB) Shares Gap Up to $2.88marketbeat.com - March 27 at 11:47 AMNuvation to buy Anheart, cancer pipeline in all-stock dealbioworld.com - March 27 at 10:19 AMNuvation Bio to buy AnHeartthepharmaletter.com - March 27 at 10:19 AMBTIG upgrades Nuvation to buy, cites AnHeart acquisitionmsn.com - March 27 at 10:19 AMNuvation Bio continues to surge as more upgrades follow after AnHeart dealmsn.com - March 27 at 10:19 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmarinNASDAQ:AMRNAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Imago BioSciencesNASDAQ:IMGOImago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Kinnate BiopharmaNASDAQ:KNTEKinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.Nuvation BioNYSE:NUVBNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.